We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
-10.17%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.15B
AUM Growth
-$1.56B
Cap. Flow
-$707M
Cap. Flow %
-17.02%
Top 10 Hldgs %
47.21%
Holding
133
New
21
Increased
21
Reduced
31
Closed
23

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$71.4M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$45.8M
3
IMTX icon
Immatics
IMTX
+$39.5M
4
CTNM
Contineum Therapeutics
CTNM
+$25.2M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$19M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$149M
2
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$146M
3
MDT icon
Medtronic
MDT
+$77M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$68.1M
5
AXSM icon
Axsome Therapeutics
AXSM
+$47.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERE
1
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$441M 10.63%
10,794,876
– –
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$278M 6.7%
28,057,456
– –
ACLX
3
DELISTED
Arcellx
ACLX
$215M 5.17%
3,889,739
-43,817
-1% -$2.38M
IOVA icon
4
Iovance Biotherapeutics
IOVA
$2.04B
$208M 5.01%
25,933,142
+6,660,151
+35% +$71.4M
NUVL
5
DELISTED
Nuvalent
NUVL
$193M 4.66%
2,549,077
-234,377
-8% -$16.7M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$7.36B
$142M 3.41%
3,446,579
+178,000
+5% +$7.11M
PCVX icon
7
Vaxcyte
PCVX
$7.71B
$141M 3.39%
1,862,608
-70,151
-4% -$4.78M
SLNO
8
DELISTED
Soleno Therapeutics
SLNO
$131M 3.15%
3,204,976
+130,434
+4% +$5.53M
ITCI
9
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$118M 2.83%
1,716,407
+661,052
+63% +$45.8M
IMTX icon
10
Immatics
IMTX
$1.18B
$94M 2.26%
8,086,159
+3,503,750
+76% +$39.5M
NBIX icon
11
Neurocrine Biosciences
NBIX
$18.3B
$89.5M 2.16%
649,909
-154,500
-19% -$21.2M
APGE icon
12
Apogee Therapeutics
APGE
$10.1B
$82.9M 2%
2,105,636
+45,241
+2% +$2.2M
MDGL icon
13
Madrigal Pharmaceuticals
MDGL
$12.5B
$74.1M 1.79%
264,600
-165,353
-38% -$39.4M
AORT icon
14
Artivion
AORT
$1.33B
$71.7M 1.73%
2,793,703
+124,725
+5% +$2.8M
SYRE icon
15
Spyre Therapeutics
SYRE
$8.34B
$71.3M 1.72%
3,031,018
+474,339
+19% +$16M
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$8.88B
$66.1M 1.59%
1,476,203
– –
EOLS icon
17
Evolus
EOLS
$397M
$62.4M 1.5%
5,753,798
– –
SWTX
18
DELISTED
SpringWorks Therapeutics
SWTX
$62.3M 1.5%
1,652,962
-609,500
-27% -$25.7M
CRGX
19
DELISTED
CARGO Therapeutics
CRGX
$60.5M 1.46%
3,683,004
+235,000
+7% +$4.47M
ATXS
20
DELISTED
Astria Therapeutics
ATXS
$59M 1.42%
6,485,420
– –
NTRA icon
21
Natera
NTRA
$36.4B
$57.4M 1.38%
530,000
-227,225
-30% -$23.1M
VRCA icon
22
Verrica Pharmaceuticals
VRCA
$92.9M
$51.8M 1.25%
709,918
– –
BHVN icon
23
Biohaven
BHVN
$2.04B
$51.6M 1.24%
1,485,232
-239,815
-14% -$9.48M
IMVT icon
24
Immunovant
IMVT
$7.86B
$50.8M 1.22%
1,923,786
-1,039,426
-35% -$29.6M
MGTX icon
25
MeiraGTx Holdings
MGTX
$1.08B
$47.7M 1.15%
11,331,103
– –
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Perceptive Advisors held 133 positions worth $4.15B, down 27% from $5.72B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors withdrew a net $707M in Q2 2024, closing 23 positions and reducing 31 holdings. Its most notable exit was Inhibrx, Inc. Common Stock, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Contineum Therapeutics worth $27.6M.

  • Perceptive Advisors's largest Q2 2024 buy was Contineum Therapeutics: 1,566,668 shares worth $27.6M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q2 2024, an estimated $71.4M increase.
  • Perceptive Advisors's biggest Q2 2024 reduction was Medtronic, cutting an estimated $77M.
  • Perceptive Advisors fully exited Inhibrx, Inc. Common Stock in Q2 2024, selling an estimated $149M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $4.15B portfolio in Q2 2024.
  • Perceptive Advisors opened 21 new positions and closed 23 in Q2 2024.
  • Perceptive Advisors's portfolio value fell 27% quarter-over-quarter to $4.15B.

Based on Perceptive Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.